AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. We discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world¡¯s most serious illnesses: cardiovascular, cancer, gastrointestinal, infection.
Booth No. D012
Lunchtime Activities | |
Dual Antiplatelet Therapy: What Have We Learnt from the Recent Trials? | |
Organized by CVRF and Supported by Educational Grant from AstraZeneca Korea | |
Wednesday, April 26 12:45 PM - 1:45 PM Presentation Theater, Level 1 |
|
Moderator(s): Yangsoo Jang, Myung-Ho Jeong | |
Panelist(s): Jang-Whan Bae, Yun-Hyeong Cho, Dongkyu Jin, Byeong-Keuk Kim, Byoung Kwon Lee, Keun-Ho Park | |
12:45 PM | Opening Remark
Speaker : Yangsoo Jang
|
12:50 PM | Insights on the Initiation and Treatment Duration of Ticagrelor in Acute Coronary Syndromes
Lecturer : Jang-Whan Bae
|
1:05 PM | Selecting the Appropriate Patients for Long-term DAPT; Insights from PEGASUS TIMI-54
Lecturer : David Joel Cohen
|
1:20 PM | Panel Discussion |
1:40 PM | Closing
Speaker : Myung-Ho Jeong
|